The University of Chicago Header Logo

Connection

Richard A. Larson to Benzamides

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Benzamides.
Richard A. Larson
Connection Strength
1.815
Benzamides
  1. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015 Apr; 94 Suppl 2:S249-57.
    View in: PubMed
    Score: 0.121
  2. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11.
    View in: PubMed
    Score: 0.112
  3. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27; 123(9):1353-60.
    View in: PubMed
    Score: 0.111
  4. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
    View in: PubMed
    Score: 0.110
  5. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8.
    View in: PubMed
    Score: 0.105
  6. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
    View in: PubMed
    Score: 0.102
  7. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct; 26(10):2197-203.
    View in: PubMed
    Score: 0.099
  8. CML: live long and prosper. Blood. 2011 Oct 27; 118(17):4499-500.
    View in: PubMed
    Score: 0.095
  9. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leuk Lymphoma. 2009 Jun; 50(6):868-70.
    View in: PubMed
    Score: 0.081
  10. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Clin Adv Hematol Oncol. 2009 Feb; 7(2):S3-5.
    View in: PubMed
    Score: 0.079
  11. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8.
    View in: PubMed
    Score: 0.076
  12. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15; 111(8):4022-8.
    View in: PubMed
    Score: 0.074
  13. Adult ALL: where are we and where are we going? Clin Adv Hematol Oncol. 2004 Jun; 2(6):342-4.
    View in: PubMed
    Score: 0.057
  14. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9.
    View in: PubMed
    Score: 0.053
  15. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
    View in: PubMed
    Score: 0.027
  16. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
    View in: PubMed
    Score: 0.025
  17. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
    View in: PubMed
    Score: 0.025
  18. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62.
    View in: PubMed
    Score: 0.024
  19. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
    View in: PubMed
    Score: 0.024
  20. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5.
    View in: PubMed
    Score: 0.022
  21. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11; 116(19):3758-65.
    View in: PubMed
    Score: 0.022
  22. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
    View in: PubMed
    Score: 0.022
  23. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
    View in: PubMed
    Score: 0.022
  24. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View in: PubMed
    Score: 0.021
  25. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51.
    View in: PubMed
    Score: 0.021
  26. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75.
    View in: PubMed
    Score: 0.020
  27. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9.
    View in: PubMed
    Score: 0.020
  28. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun; 23(6):1054-61.
    View in: PubMed
    Score: 0.020
  29. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60.
    View in: PubMed
    Score: 0.020
  30. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View in: PubMed
    Score: 0.019
  31. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.019
  32. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.
    View in: PubMed
    Score: 0.018
  33. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 01; 110(7):2309-15.
    View in: PubMed
    Score: 0.018
  34. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15; 109(10):4143-50.
    View in: PubMed
    Score: 0.017
  35. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17.
    View in: PubMed
    Score: 0.017
  36. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20.
    View in: PubMed
    Score: 0.016
  37. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84.
    View in: PubMed
    Score: 0.016
  38. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88.
    View in: PubMed
    Score: 0.014
  39. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6.
    View in: PubMed
    Score: 0.014
  40. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003 Jun 01; 21(11):2138-46.
    View in: PubMed
    Score: 0.013
  41. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004.
    View in: PubMed
    Score: 0.013
  42. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.